# US 2026/0234173 A1 · Structured molecular vectors for anti-inflammatory compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0234173 A1
- Document ID: US20260234173A1
- Status: Published application
- Kind: A1
- Application number: 19/638,374
- Filed: 2026-04-03
- Published: 2026-08-13
- Earliest claimed: 2019-02-21
- Assignees: Universite Claude Bernard Lyon 1; Centre National De La Recherche Scientifique; Institut National de la Sante et de la Recherche Medicale; Universite Jean Monnet Saint Etienne
- Applicants: Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique; Institut National de la Sante et de la Recherche Medicale; Universite Jean Monnet Saint Etienne
- Inventors: Jacques BODENNEC; Amor BELMEGUENAÏ; Selena BODENNEC; Laurent BEZIN; Béatrice GEORGES; Victor BLOT
- Web page: https://patentgrep.com/patent/US20260234173A1

## CPC

- A61K 31/131: acyclic
- C07F 9/4009: {Esters containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)}
- A23L 29/04: {Fatty acids or derivatives}
- A23L 33/12: Fatty acids or derivatives thereof
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 31/662: Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 31/688: both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07F 9/3817: {Acids containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to structured molecular vectors of formula (I), compounds of formula (II) and pharmaceutical compositions comprising such compounds. The invention also relates to such pharmaceutical compositions for use for preventing and/or treating a disease chosen among an inflammatory disease or a disease associated with a cognitive disorder. The invention further relates to such pharmaceutical compositions for use for preventing cognitive decline or restoring cognitive functions altered in brain injuries and/or in traumatic brain injuries and/or in a neuroinflammatory disease, and/or in a neurodegenerative disease.

## Claims

### Claim 1

A compound of formula (IIA):
wherein
R5 represents a saturated or unsaturated fatty acyl comprising from 2 to 30 carbon atoms or one of its oxygen derivatives; and
R7 represents a hydrogen or an (C1-C6) alkyl group,
and hydrates, diastereomers, or pharmacologically acceptable salts thereof.

### Claim 2 (depends on 1)

The compound, hydrate, diastereomer, or pharmaceutically acceptable salt according to claim 1,
wherein
R5 represents a saturated or unsaturated fatty acyl comprising from 2 to 30 carbon atoms, which is docosahexaenoic acid; and
R7 represents a (C1-C6)alkyl group.

### Claim 3 (depends on 1)

The compound, hydrate, diastereomer, or pharmaceutically acceptable salt according to claim 1, wherein R5 has 22 carbon atoms.

### Claim 4 (depends on 3)

The compound, hydrate, diastereomer, or pharmaceutically acceptable salt according to claim 3, wherein R5 is docosahexaenoic acid and the compound has the structure:

### Claim 5 (depends on 3)

The compound, hydrate, diastereomer, or pharmaceutically acceptable salt according to claim 3, which is the pharmaceutically acceptable salt of synaptamide phosphonate.

### Claim 6 (depends on 5)

A pharmaceutical composition comprising the pharmaceutically acceptable salt of synaptamide phosphonate according to claim 5, and an acceptable pharmaceutical excipient.

### Claim 7 (depends on 6)

A method of treating an inflammatory disease or a disease associated with a cognitive disorder comprising the administration of a pharmaceutical composition according to claim 6, to a subject in need of treatment.
